azacitidine has been researched along with Anemia, Fanconi in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keck, JL; Manthei, KA; Voter, AF | 1 |
| Ma, J; Morimoto, K; Parekh, C; Pulsipher, MA | 1 |
| Berot, A; Pluchart, C | 1 |
| Abu-Arja, R; Abusin, G; Cabral, L; Ding, H; Hashem, H; Lazarus, HM; Rangarajan, H | 1 |
| Li, M; Lu, S; Wang, H; Wang, Z; Zhang, Y | 1 |
1 review(s) available for azacitidine and Anemia, Fanconi
| Article | Year |
|---|---|
Venetoclax and Azacitidine in the Treatment of
Topics: Azacitidine; Fanconi Anemia; Humans; Leukemia; Nuclear Proteins | 2023 |
4 other study(ies) available for azacitidine and Anemia, Fanconi
| Article | Year |
|---|---|
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanconi Anemia; High-Throughput Screening Assays; Humans; Multiprotein Complexes; Protein Interaction Maps; RecQ Helicases | 2016 |
Treatment With Azacitidine in the Context of Palliative Care for a Patient With Acute Myeloid Leukemia Complicating Fanconi Anemia With Biallelic FANCD1/BRCA 2 Mutations.
Topics: Antimetabolites, Antineoplastic; Azacitidine; BRCA2 Protein; Fanconi Anemia; Female; Humans; Infant; Leukemia, Myeloid, Acute; Mutation; Palliative Care | 2018 |
Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
Topics: Adolescent; Azacitidine; Cytotoxins; DNA Damage; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Topics: Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Fanconi Anemia; Fanconi Anemia Complementation Group F Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |